Skip to content

Scribe Therapeutics, Inc.

SCTX· NasdaqCore metricsCIK 1853921

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · +0.44%
Market cap
$321.46M
18.94M shares
Filings
48
$1.64M
Q3 2026
—
-$9.86M
Q3 2026
—
-$10.86M
Q3 2026
—
-$24.18M
Q3 2026derived
—
-$0.68
Q3 2026
—
$172.05M
Q3 2026−3.6% FY25 yoy
$321.46M
—
—
2.6×
—
—

FY2026 figures · derived

Price

$16.9821.59%$4.67since Jul 24, 2026
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$1.64MQ3 2026
No annual history for this metric yet.
PeriodEndedValueKindSource trail

Biological products, except diagnostic substances

Scribe Therapeutics, Inc. is the 76th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Scribe Therapeutics, Inc. · CIK 1853921 · Engraved from SEC EDGAR